VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

IBDV DNA vaccine pCAGoptiVP2/rVP2 IBDV DNA vaccine pCAGVP243-IL-18 Infectious Bursal Disease Virus DNA Vaccine expressing VP2 rFPV-IBDV-VP 2.4.3 rFPV-IBDV-VP2 rMDV-IBDV-VP2
Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004533
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Chickens
  • VP2 gene engineering:
    • Type: DNA vaccine construction
    • Description: The synthetic gene for VP2 protein of vvIBDV Gx with codons optimized for chicken usage was synthesized and cloned into pCAGGS vector (Gao et al., 2013).
    • Detailed Gene Information: Click Here.
  • Vector: pCAGGS prime, rVP2 protein boost (Gao et al., 2013)
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004534
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Chickens
  • Antigen: VP243 gene of vvIBDV HLJ0504 (VP243 can be cleaved into VP2, VP3, and VP4) (Li et al., 2013)
  • VP2-VP4-VP3 gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Vector: pCAGGS (Li et al., 2013)
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004585
  • Type: DNA vaccine
  • Status: Research
  • VP2 gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Vector: pIRES (Kumar et al., 2009)
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004750
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • VP2-VP4-VP3 gene engineering:
    • Type: Recombinant vector construction
    • Description: Recombinant FPV-VP 2.4.3 contained the gene for the VP 2-VP4-VP3 polyprotein under the control of the vaccinia virus late promoter P.L 11 inserted within the thymidine kinase (TK) gene of FPV (Heine and Boyle, 1993).
    • Detailed Gene Information: Click Here.
  • Preparation: Recombinant FPV-VP 2.4.3 contained the gene for the VP 2-VP4-VP3 polyprotein under the control of the vaccinia virus late promoter P.L 11 inserted within the thymidine kinase (TK) gene of FPV (Heine and Boyle, 1993).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004625
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Chicken
  • VP2 gene engineering:
    • Type: Recombinant vector construction
    • Description: Marek's disease and Fowlpox viruses expressing the vvIBDV host-protective antigen VP2 (rMDV, rFPV) (Tsukamoto et al., 2000).
    • Detailed Gene Information: Click Here.
  • Preparation: Marek's disease and Fowlpox viruses expressing the vvIBDV host-protective antigen VP2 (rMDV, rFPV) (Tsukamoto et al., 2000).
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004749
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • VP2 gene engineering:
    • Type: Recombinant vector construction
    • Description: IBDV host-protective antigen VP2 was expressed in a recombinant vaccine vector (Tsukamoto et al., 2000).
    • Detailed Gene Information: Click Here.
  • Preparation: Marek's disease and Fowlpox viruses expressing the vvIBDV host-protective antigen VP2 (rMDV, rFPV) (Tsukamoto et al., 2000).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response Host Response Host Response Host Response Host Response Host Response

Chicken Response

  • Immune Response: Chickens in the DNA prime–protein boost group developed significantly higher levels of ELISA and neutralizing antibodies to IBDV compared with those immunized with either the DNA vaccine or the protein vaccine alone (P < 0.05). Furthermore, the highest levels of lymphocyte proliferation response, IL-4 and IFN-γ production were induced following priming with the DNA vaccine and boosting with the rVP2 protein (Gao et al., 2013).
  • Efficacy: Chickens inoculated with the DNA prime–protein boost vaccine had 100% protection against challenge with vvIBDV, as evidenced by the absence of clinical signs, mortality, and bursal atrophy. In contrast, chickens receiving the DNA vaccine and the rVP2 protein vaccine had 67% and 80% protection, respectively (Gao et al., 2013).

Chicken Response

  • Immune Response: Chickens immunized with plasmid pCAGVP243-IL-18 carrying both VP243 and IL-18 genes induced significantly higher levels of antibodies, lymphocyte proliferation responses and of the cytokines IL-4 and IFN-γ than those injected with pCAGVP243 encoding the VP243 gene alone (Li et al., 2013).
  • Efficacy: Furthermore, pCAGVP243-IL-18 provided higher protection (93%) against vvIBDV challenge in chickens than pCAGVP243 (60%), as evidenced by the absence of clinical signs, mortality, and bursal atrophy (Li et al., 2013).

Chicken Response

  • Vaccination Protocol: The birds were immunized intramuscularly with 50 μg plasmid DNA in the quadricep muscle of the hind limb (Kumar et al., 2009).
  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Birds immunized with pibdVP2-IRES-chiIL-2 plasmid at 21 days post-challenge showed the highest antibody titer. In addition, blood analysis showed a proliferation of CD4-positive cells in the group vaccinated with pibdVP2-IRES-chiIL-2 (Kumar et al., 2009).
  • Challenge Protocol: All vaccinated birds and the unvaccinated control birds were challenged with 105 ELD50 (50% embryo lethal dose) virulent IBDV (strain KT1/99) through the intrabursal and intraocular routes at 21 days post-immunization (Kumar et al., 2009).
  • Efficacy: Birds vaccinated with the pibdVP2-IRES-chiIL-2 plasmid showed an 80% protection efficacy (Kumar et al., 2009).

Chicken Response

  • Vaccination Protocol: Vaccination with FPV-VP2 (Heine and Boyle, 1993).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: The birds were challenged with IBDV (strain 002-73) (Heine and Boyle, 1993).
  • Efficacy: A significant level of protection was provided by FPV-VP2 vaccination, although the level was lower than the protection provided by an oil adjuvanted inactivated whole IBDV vaccine. Birds vaccinated with FPV-VP2.4.3 were not protected from infection as assessed by ELISA for the presence of IBD virus in bursae (Heine and Boyle, 1993).

Chicken Response

  • Vaccination Protocol: Chickens vaccinated with the rFPV or rMDV alone, or vaccinated simultaneously with both at their hatch (rMDV-rFPV(1d)) (Tsukamoto et al., 2000).
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Most chickens were protected against developing clinical signs and mortality; however, only zero to 14% of the chickens were protected against gross lesions (Tsukamoto et al., 2000).

Chicken Response

  • Vaccination Protocol: Chickens vaccinated with the rFPV or rMDV alone, or vaccinated simultaneously with both at their hatch (rMDV-rFPV(1d)) (Tsukamoto et al., 2000).
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Most chickens were protected against developing clinical signs and mortality; however, only zero to 14% of the chickens were protected against gross lesions (Tsukamoto et al., 2000).
References References References References References References
Gao et al., 2013: Gao H, Li K, Gao L, Qi X, Gao Y, Qin L, Wang Y, Wang X. DNA prime-protein boost vaccination enhances protective immunity against infectious bursal disease virus in chickens. Veterinary microbiology. 2013; 164(1-2); 9-17. [PubMed: 23419823].
Li et al., 2013: Li K, Gao H, Gao L, Qi X, Gao Y, Qin L, Wang Y, Wang X. Adjuvant effects of interleukin-18 in DNA vaccination against infectious bursal disease virus in chickens. Vaccine. 2013; 31(14); 1799-1805. [PubMed: 23395585].
Kumar et al., 2009: Kumar S, Ahi YS, Salunkhe SS, Koul M, Tiwari AK, Gupta PK, Rai A. Effective protection by high efficiency bicistronic DNA vaccine against infectious bursal disease virus expressing VP2 protein and chicken IL-2. Vaccine. 2009; 27(6); 864-869. [PubMed: 19111591].
Heine and Boyle, 1993: Heine HG, Boyle DB. Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens. Archives of virology. 1993; 131(3-4); 277-292. [PubMed: 8394069].
Tsukamoto et al., 2000: Tsukamoto K, Sato T, Saito S, Tanimura N, Hamazaki N, Mase M, Yamaguchi S. Dual-viral vector approach induced strong and long-lasting protective immunity against very virulent infectious bursal disease virus. Virology. 2000; 269(2); 257-267. [PubMed: 10753704].
Tsukamoto et al., 2000: Tsukamoto K, Sato T, Saito S, Tanimura N, Hamazaki N, Mase M, Yamaguchi S. Dual-viral vector approach induced strong and long-lasting protective immunity against very virulent infectious bursal disease virus. Virology. 2000; 269(2); 257-267. [PubMed: 10753704].